Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

被引:140
|
作者
Kapoor, Prashant [1 ]
Kumar, Shaji K. [1 ]
Dispenzieri, Angela [1 ]
Lacy, Martha Q. [1 ]
Buadi, Francis [1 ]
Dingli, David [1 ]
Russell, Stephen J. [1 ]
Hayman, Suzanne R. [1 ]
Witzig, Thomas E. [1 ]
Lust, John A. [1 ]
Leung, Nelson [1 ]
Lin, Yi [1 ]
Zeldenrust, Steven R. [1 ]
McCurdy, Arleigh [1 ]
Greipp, Philip R. [1 ]
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
Gertz, Morie A. [1 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
关键词
BORTEZOMIB PLUS DEXAMETHASONE; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE MELPHALAN; FREE LIGHT-CHAIN; INDUCTION TREATMENT; THERAPY; THALIDOMIDE; CONSOLIDATION; PREDNISONE; REMISSION;
D O I
10.1200/JCO.2013.49.0086
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To study the impact of achieving stringent complete response (sCR), an increasingly attainable goal, after autologous stem-cell transplantation (ASCT) in patients with multiple myeloma (MM). Patients and Methods Maximal response rates were determined in 445 consecutive patients who underwent ASCT within 12 months of diagnosis of MM. The patients achieving varying degrees of complete response (CR) are the focus of our study. Results One hundred and nine patients (25%) achieved sCR after ASCT. The median overall survival (OS) rate from the time of transplantation for patients attaining sCR was not reached (NR), in contrast to those patients achieving conventional complete response (CR; n = 37; OS, 81 months) or near CR (nCR; n = 91; OS, 60 months; P < .001). Five-year OS rates were 80%, 53%, and 47% for sCR, CR, and nCR, respectively. The median time to progression (TTP) from ASCT of patients achieving sCR was significantly longer (50 months) than TTP of patients achieving CR or nCR (20 months and 19 months, respectively). On multivariable analysis, post-ASCT response of sCR was an independent prognostic factor for survival (hazard ratio, 0.44; 95% CI, 0.25 to 0.80; versus CR; P = .008), in addition to proliferation rate, pre-ASCT cytogenetics, and performance status. OS rates of patients attaining sCR continued to remain superior at 2-year landmark (median, NR v 70 months for conventional CR group; P = .007). Conclusion Improved long-term outcome is seen after ASCT with achievement of sCR when compared with lesser degrees of responses. Myeloma trials reporting the response rates should identify patients achieving sCR and CR separately, owing to markedly disparate outcomes of the two categories.
引用
收藏
页码:4529 / +
页数:8
相关论文
共 50 条
  • [41] Effect of complete response on outcome following autologous stem cell transplantation for myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Witzig, TE
    Lust, JA
    Larson, D
    Therneau, TM
    Kyle, RA
    Litzow, MR
    Greipp, PR
    Gertz, MA
    BONE MARROW TRANSPLANTATION, 2000, 26 (09) : 979 - 983
  • [42] Immune Reconstitution after Autologous Stem Cell Transplantation for Multiple Myeloma
    Chung, David J.
    Pronschinske, Katherine B.
    Shyer, Justin A.
    Wu, Vernon
    Hassoun, Hani
    Landau, Heather
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Koehne, Guenther
    Giralt, Sergio A.
    Young, James W.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S60 - S62
  • [43] Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma
    Grosskreutz, CL
    Egan, R
    Scigliano, E
    Fruchtman, SM
    Isola, LM
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 73 - 73
  • [44] Effect of complete response on outcome following autologous stem cell transplantation for myeloma
    SV Rajkumar
    R Fonseca
    A Dispenzieri
    MQ Lacy
    TE Witzig
    JA Lust
    D Larson
    TM Therneau
    RA Kyle
    MR Litzow
    PR Greipp
    MA Gertz
    Bone Marrow Transplantation, 2000, 26 : 979 - 983
  • [45] AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN HIGH-RISK MULTIPLE-MYELOMA
    REIFFERS, J
    MARIT, G
    BOIRON, JM
    BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (02) : 296 - 297
  • [46] Is There an Optimal Timing of Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Agents?
    Toprak, Selami Kocak
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 338 - 339
  • [47] Symptom burden after autologous stem cell transplantation for multiple myeloma
    Campagnaro, Erica
    Saliba, Rima
    Giralt, Sergio
    Roden, Linda
    Mendoza, Floralyn
    Aleman, Ana
    Cleeland, Charles
    Weber, Donna
    Brown, Jane
    Anderson, Karen O.
    CANCER, 2008, 112 (07) : 1617 - 1624
  • [48] Myelodysplasia after autologous stem cell transplantation for multiple myeloma.
    Franz, Gregory
    McClune, Brian
    Buadi, Francis
    Walsh, William
    White, Frank
    Przepiorka, Donna
    BLOOD, 2006, 108 (11) : 424B - 424B
  • [49] Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    McCarthy, Philip L.
    Holstein, Sarah A.
    Petrucci, Maria Teresa
    Richardson, Paul G.
    Hulin, Cyrille
    Tosi, Patrizia
    Bringhen, Sara
    Musto, Pellegrino
    Anderson, Kenneth C.
    Caillot, Denis
    Gay, Francesca
    Moreau, Philippe
    Marit, Gerald
    Jung, Sin-Ho
    Yu, Zhinuan
    Winograd, Benjamin
    Knight, Robert D.
    Palumbo, Antonio
    Attal, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3279 - +
  • [50] Improved survival with salvage autologous stem-cell transplantation in myeloma
    Holstein, Sarah A.
    McCarthy, Philip L.
    LANCET HAEMATOLOGY, 2016, 3 (07): : E306 - E307